Stock NEOG NEOGEN CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Neogen Corporation

Equities

NEOG

US6404911066

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
12.14 USD +1.51% Intraday chart for Neogen Corporation +4.57% -39.63%
Apr. 18 Neogen Corporation Forms Genomics Relationship with Performance Food Group CI
Apr. 15 Piper Sandler Adjusts Price Target on Neogen to $17 From $19, Maintains Neutral Rating MT

Valuation

Fiscal Period: May 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,937 3,768 4,957 2,852 3,782 2,591 - -
Enterprise Value (EV) 1 2,937 3,768 4,576 2,852 3,782 2,591 2,591 2,591
P/E ratio 49 x 63 x 81 x 58.8 x -146 x -342 x 797 x 120 x
Yield - - - - - - - -
Capitalization / Revenue 7.09 x 9.01 x 10.6 x 5.41 x 4.6 x 2.84 x 2.76 x 2.65 x
EV / Revenue 7.09 x 9.01 x 10.6 x 5.41 x 4.6 x 2.84 x 2.76 x 2.65 x
EV / EBITDA 34.3 x 43.9 x 52.1 x 34.7 x 18.4 x 12.2 x 11.6 x 10.1 x
EV / FCF 59,717,895 x - 91,160,723 x - -152,925,802 x - - -
FCF Yield 0% - 0% - -0% - - -
Price to Book 4.63 x - - - - - - -
Nbr of stocks (in thousands) 104,241 105,822 107,400 107,797 216,221 216,608 - -
Reference price 2 28.18 35.61 46.16 26.46 17.49 11.96 11.96 11.96
Announcement Date 7/23/19 7/21/20 7/20/21 7/26/22 7/27/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: May 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 414.2 418.2 468.5 527.2 822.4 912.2 937.6 977.9
EBITDA 1 85.72 85.92 95.21 82.31 205.4 212.1 224.3 256.5
EBIT 1 68.09 67.52 74.17 58.62 37.52 57.72 69.96 91.68
Operating Margin 16.44% 16.15% 15.83% 11.12% 4.56% 6.33% 7.46% 9.37%
Earnings before Tax (EBT) 1 72.96 72.3 75.27 60.21 -22.04 -13.03 3.63 27.47
Net income 1 60.18 59.48 60.88 48.31 -22.87 -8.076 2.954 21.92
Net margin 14.53% 14.22% 13% 9.16% -2.78% -0.89% 0.32% 2.24%
EPS 2 0.5750 0.5650 0.5700 0.4500 -0.1200 -0.0350 0.0150 0.1000
Free Cash Flow 49.18 - 54.38 - -24.73 - - -
FCF margin 11.87% - 11.61% - -3.01% - - -
FCF Conversion (EBITDA) 57.38% - 57.11% - - - - -
FCF Conversion (Net income) 81.73% - 89.32% - - - - -
Dividend per Share - - - - - - - -
Announcement Date 7/23/19 7/21/20 7/20/21 7/26/22 7/27/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: May 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales 1 130.5 128.2 140.1 132.3 230 218.3 241.8 229 229.6 228.8 224.8 228.8 233.6 238.4 236.7
EBITDA 1 18.3 12.7 23.89 25.52 64.05 51.27 63.08 52.37 55.1 52.74 51.45 56 58 57 56
EBIT 1 12.47 16.98 18.03 19.79 -7.656 15.68 23.42 19.14 14.46 12.02 12.11 16.4 16.6 14.3 12.9
Operating Margin 9.55% 13.24% 12.87% 14.96% -3.33% 7.19% 9.69% 8.36% 6.3% 5.25% 5.39% 7.17% 7.1% 6% 5.45%
Earnings before Tax (EBT) 1 - - 18.91 6.659 -34.09 -2.26 7.65 1.663 -3.747 -5.822 -5.128 -0.6 -1.1 -3 -3.9
Net income 1 - - 14.96 5.209 -41.84 8.19 5.572 1.503 -3.487 -2.022 -4.072 -0.5 -0.8 -2.4 -3.1
Net margin - - 10.68% 3.94% -18.19% 3.75% 2.3% 0.66% -1.52% -0.88% -1.81% -0.22% -0.34% -1.01% -1.31%
EPS 2 - - 0.1400 0.0500 -0.1900 0.0400 0.0300 0.0100 -0.0200 -0.0100 -0.0150 - - -0.0100 -0.0100
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 12/21/21 3/24/22 7/26/22 9/27/22 1/5/23 3/30/23 7/27/23 10/10/23 1/9/24 4/9/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: May 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - 381 - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 49.2 - 54.4 - -24.7 - - -
ROE (net income / shareholders' equity) 10% - 8.32% - - - - -
ROA (Net income/ Total Assets) 9.16% - 7.09% - - - - -
Assets 1 656.9 - 858.7 - - - - -
Book Value Per Share 6.080 - - - - - - -
Cash Flow per Share 0.6100 - 0.7600 - - - - -
Capex 14.7 - 26.7 - 65.8 - - -
Capex / Sales 3.54% - 5.7% - 8% - - -
Announcement Date 7/23/19 7/21/20 7/20/21 7/26/22 7/27/23 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Neogen Corporation

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
11.96 USD
Average target price
17 USD
Spread / Average Target
+42.14%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
NEOGEN CORPORATION Stock Neogen Corporation
-39.63% 2.59B
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 185B
MEDTRONIC PLC Stock Medtronic plc
-3.20% 105B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.59B
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 54.66B
CENCORA, INC. Stock Cencora, Inc.
+17.29% 47.78B
HOYA CORPORATION Stock Hoya Corporation
+4.06% 41.26B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.95B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.37B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.8B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. NEOG Stock
  4. Financials Neogen Corporation